Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-01-18
2011-11-15
Strzelecka, Teresa E (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C435S091200, C536S023100
Reexamination Certificate
active
08058003
ABSTRACT:
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.
REFERENCES:
patent: 2003012067 (2003-02-01), None
patent: 2005106488 (2005-11-01), None
Dorsam, R. T. et al., Nature Reviews, Cancer, vol. 7, pp. 79-94 (2007).
Schuller, H.M. et al., Cancer Res., vol. 59, pp. 4510-4515 (1999).
Thaker, P. H. et al., Nature Med., vol. 12, pp. 939-944 (2006).
Yang J. et al. “Transcriptional and posttranscriptional regulation of beta2-adrenergic receptor gene in rat liver during sepsis” Am. J. Physiol., Jul. 1999, vol. 271 No. I PI. 2, pp. R132-9.
Yu Jin et al., “Integrative Genornics Analysis Reveals Silencing of Beta-Adrenergic Signaling by Polycomb in Prostate Cancer”, Cancer Cell, Nov. 2007, 12(5):419-431.
Ringrose and Paro, “Repair and Genetic Consequences of Endogenous DNA Base Damage in Mammalian Cells” Annual Review Genetics, 2004, 38:413-443.
Mulholland et al, “Regulation of Polycomb Group Complexes by the Sequences-Specific DNA Binding Proteins Zeste and Gaga,” Genes Dev 2003 17:2741-2746.
Boyer et al., “Polycomb Complexes Repress Developmental Regulators in Murine Embryonic Stem Cells” Nature 2006 441(7091): 349-53.
Lee et al, “Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells” Cell 2006 125:301-313.
Rank et al, “Transcription Through Intergenic Chromosomal Memory Elements of theDrosophilaBithorax Complex Correlates With an Epigenetic Switch,” Mol Cell Biol 2002 22: 8026-8034.
Francis and Kingston, “Mechanisms of Transcriptional Memory” Nature Review: Molecular Cell Biology 2001, 2: 409-421.
Levine et al,“The Core of the Polycomb Repressice Complex Is Compositionally and Functionally Conserved in Files and Humans,” Mol Cell Biol, 2002 22:6070-6078.
Rastelli et al., “Related Chromosome Binding Sites for Zeste, Suppressors of Zeste and Polycomb Group Proteins inDrosophilaand Their Dependence on Enhancer of Zeste Function” EMBO 1993 12:1513-1522.
Kirmizis et al, “Silencing of Human Polycomb Target Genes Is Associates With Methylation of Histone H3 LYS 27,” Genes Dev. 2004 18:1592-1605.
Cao et al., “Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing” Science 2002, 298:1039-1043.
Kuzmichev et al, “Histone Methyltransferase Activity Associated With a Human Muliprotein Compex Containing the Enhancer of Zeste Protein,” Genes Dev. 2002 16:2893-2905.
Czermin et al., “DrosophilaEnhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity That Marks Chromosomal Polycomb Sites” Cell Oct. 2002, 111:185-196.
Varambally et al, “The Polycomb Group Protein EZH2 is Involved in Progression of Prostate Cancer,” Nature 2002, 419:624-629.
Bracken et al, “Genome-Wide Mapping of Polycomb Target Genes Unravels Their Roles in Cell Fate Transitions,” Genes Dev 20, 1123-1136, 2006.
Visser et al., “The Polycomb Group Protein EZH2 is Upregulated in Proliferating, Cultured Human Mantle Cell Lymphoma.” Br J Haematology 2001 112:950-958.
Bachmann et al, “EZH2 Expression is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast” J Clin Oncol. 2006 24:268-273.
Collett et al, “Expression of Enhancer of Zeste Homologue 2 Is Significantly Associated With Increased Tumor Cell Proliferation and is a Marker of Aggressive Breast Cancer,” Clin Cancer Res. 2006 12:1168-1174.
Matsukawa et al., “Expression of the Enhancer of Zeste Homolog 2 is Correlated With Poor Prognosis in Human Gastric Cancer.” Cancer Science, 2006 97:484-491.
Raaphorst et al, “Poorly Differentiated Breast Carcinoma is Associated With Increased Expression of the Human Polycomb Group EZH2 Gene,” Neoplasia Nov./Dec. 2003 5:481-488.
Kleer et al, “EZH2 is a Marker of Aggresive Breast Cancer and Promotes Neoplastic Transformation of Breast Epithelial Cells,” Proc Natl Acad Sci USA, 2003, 100, 11606-11611.
Croonquist & Van Ness, “The Polycomb Group Protein Enhancer of Zeste Homolog 2 (EZH2) is an Oncogene That Influences Myeloma Cell Growth and the Mutant RAS Phenotype” Oncogene 2005 24:6269-6280.
Bracken et al., “EZH2 is Downstream of the PRB-E2F Pathway, Essential for Proliferation and Amplied in Cancer” The EMBO Journal, 2003 22(20):5323-5335.
Bos, “Linking Rap to Cell Adhesion”, Curr Opin Cell Biol., Apr. 2005 7(2):123-8.
Bos et al., “RAP1 Signalling: Adhering to New Models” Nat Rev Mol Cell Biol May 2001 2:369-377.
Stork and Schmitt, “Crosstalk Between Camp and Map Kinase Signaling in the Regulation of Cell Proliferation” Trends Cell Biol 2002 12: 258-266.
Daaka, “G Proteins in Cancer: The Prostate Cancer Paradigm” Sci. STKE Jan. 13, 2004 (216):RE2.
Price et a, “RAP1 Regulates E-Cadherin-Mediated Cell-Cell Adhesion,” J Biol Chem 2004 279:35127-35132.
De Rooij et al., “EPAC is a RAP1 Guanine-Nucleotide-Exchange Factor Directly Activated by Cyclic AMP” Nature 1998 396:474-477.
Crespo et al., “Dual Effect of B-Adrenergic Receptors on Mitogen-Activated Protein Kinase” J Biol Chem 1995 270:25259-25265.
Cook and McCormick, “Inhibition by Camp of RAS-Dependent Activation of RAF.” Science Nov. 12, 1993 262(5136):1069-1072.
Kitayama et al., “A RAS-Related Gene With Transformation Suppressor Activity” Cell 1989 56:77-84.
Thaker et al., “Chronic Stress Promotes Tumor Growth and Angiogenesis in a Mouse Model of Ovarian Carcinoma” Nat Med 2006 12: 939-944.
Bos et al, “The Role of RAP1 in Integrin-Mediated Cell Adhesion,” Biochem Soc Trans 2003 31:83-86.
Vander Griend and Rinker-Schaeffer, “A New Look at an old Problem: The Survival and Organ-Specific Growth of Metastases” Sci STKE 2004, PE3.
Kuiperij et al., “Activation of FOXO Transcription Factors Contributes to the Antiproliferative Effect of Camp.” Oncogene 2005 24:2087-2095.
Yan et al., “Beta-Adrenergic Receptor/Camp-Mediated Signaling and Apoptosis of S49 Lymphoma Cells” Am J Physiol Cell Physiol. 2000 279, C1665-1674.
Gioeli et al., “Activation of Mitogen-Activated Protein Kinase Associated With Prostate Cancer Progression” Cancer Res 1999 59:279-284.
Rhodes et al, “Oncomine: A Cancer Microarray Database and Integrated Data-Mining Platform” Neoplasia 2004 6:1-6.
Glinsky et al, “Gene Expression Profiling Predicts Clinical Outcome of Prostate Cancer,” J. Clin Invest 2004 113(6):913-923.
Yu et al, “Gene Expression Alterations in Prostate Cancer Predicting Tumor Agression and Preceding Development of Malignancy,” J. Clin Oncol. 2004 22:2790-2799.
Huang et al, “Gene Expression Predictors of Breast Cancer Outcomes,” Lancet 2003 361: 1590-1596.
Van'T Veer et al, “Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer” Nature 2002 415:530-536.
Tan et al, “Pharmacologic Disruption of Polycomb-Repressive Complex 2-Mediated Gene Repression Selectively Induces Apoptosis in Cancer Cells,” Genes Dev 2007 21:1050-1063.
Varambally et al, “Intergrative Genomic and Proteomic Analysis of Prostate Cancer Reveals Signatures of Metastic Progression,” Cancer Cell 2005 8:393-406.
Ramaswamy et al, “Multiclass Cancer Diagnosis Using Tumor Gene Expression Signatures,” Proc Natl Acad Sci USA, 2001, 98, 15149-15154.
Chinnaiyan Arul M.
Mehra Rohit
Yu Jindan
Casimir Jones S.C.
Strzelecka Teresa E
The Regents of the University of Michigan
LandOfFree
ADRB2 cancer markers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ADRB2 cancer markers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ADRB2 cancer markers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4279498